Bone Biologics Reports 2026 Annual Meeting Vote Results

What Happened

• Bone Biologics Corporation filed an 8-K on Sept. 29, 2026 reporting results from its Annual Meeting held Sept. 28, 2026. Stockholders elected four director nominees (Bruce Stroever, Siddhesh Angle, Robert Gagnon, Philip Meikle) and approved several proposals including advisory approval of executive compensation, ratification of the independent auditor, authorization related to certain warrant issuances (Nasdaq Rule 5635(d) compliance), and an amendment to permit a reverse stock split in a range of 1-for-2 to 1-for-10. Because the material proposals were approved, no adjournment was necessary.

Key Details

• Shares: 2,011,057 shares were entitled to vote; 951,746 shares were present or represented by proxy. Broker non-votes totaled 758,866 on several proposals.
• Directors elected (votes For / Withheld / Broker non-votes): Bruce Stroever 152,615 / 3,941 / 758,866; Siddhesh Angle 155,570 / 3,842 / 758,866; Robert Gagnon 158,799 / 3,892 / 758,866; Philip Meikle 158,783 / 3,891 / 758,866.
• Say-on-pay (advisory): Approved — 139,592 For, 49,851 Against, 3,437 Abstentions; 758,866 broker non-votes.
• Auditor ratified: Weinberg & Company, P.A. approved — 898,011 For, 49,834 Against, 3,901 Abstentions.
• Nasdaq compliance / warrants: Approved — 147,340 For, 42,233 Against, 3,307 Abstentions; this permits potential issuance of shares underlying certain warrants equal to or exceeding 20% of outstanding common stock immediately prior to issuance.
• Reverse split authorization: Approved amendment allowing the board discretion to effect a reverse split between 1-for-2 and 1-for-10 (Votes: 806,603 For, 137,720 Against, 7,423 Abstentions).

Why It Matters

• Governance: The board’s slate was elected, so current management/board direction remains intact. The advisory approval of executive compensation (say-on-pay) signals stockholder support for reported pay practices, though it is non-binding.
• Capital structure and Nasdaq compliance: Approval to allow issuance of shares underlying certain warrants (potentially ≥20% of outstanding shares) and the reverse-split authorization give the board flexibility to adjust share count and meet Nasdaq listing rules or financing needs. A reverse split (if implemented) would reduce outstanding shares and increase per-share price but would not change holders’ proportional ownership (except for effects on fractional shares).
• Auditor ratification: Stockholders ratified Weinberg & Company, P.A. as the independent registered public accounting firm for fiscal 2026, confirming continuity in external audit oversight.